Recent News

• 12.23.2025 - Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate
• 12.03.2025 - Artelo Biosciences Announces Publication of New Peer-Reviewed Study Demonstrating Intraperitoneal Administration of a Novel Fatty Acid Binding Protein 5 (FABP5) Inhibitor Significantly Reduces Stress-Induced Anxiety and Depression Behaviors in Preclinical Models
• 11.12.2025 - Artelo Biosciences Provides Business Update and Reports Third Quarter 2025 Financial Results
• 11.04.2025 - Artelo Biosciences Announces Publication of Peer-Reviewed Article on Role of Fatty Acid Binding Proteins in Cancer

Recent Filings

• 12.11.2025 - ARS Annual Report to Security Holders
• 12.11.2025 - DEF 14A Other definitive proxy statements
• 12.02.2025 - EFFECT Notice of Effectiveness
• 11.25.2025 - 8-K Current report
• 11.17.2025 - 3 Initial statement of beneficial ownership of securities
• 11.17.2025 - S-1 General form for registration of securities under the Securities Act of 1933
• 11.14.2025 - 8-K Current report
• 11.12.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 11.10.2025 - D Notice of Exempt Offering of Securities
• 10.31.2025 - 8-K Current report